IBC LIFE SCIENCES

2015 年 5 月 19 日至 22 日，上海金茂君悦大酒店

Part of BIOPHARMA DEVELOPMENT & PRODUCTION WEEK

6TH ANNUAL

BIOSIMILARS ASIA

2015 年第 6 届亚洲生物仿制药年会

19 - 22 May 2015

Grand Hyatt Shanghai, China

Successfully Navigating the Biosimilars Landscape and Shaping Opportunity in 2015 and Beyond

把握生物仿制药发展前景，迎接 2015及未来机遇

Dr Shin Jae Chang
Vice President,
Celltrion, Korea

Ira Jacobs
Global Oncology Lead, Biosimilars,
Pfizer, US

Dr. Martina A. Sersch
Global Clinical Lead, Oncology Global Development, APAC Biotherapeutics Lead,
Genentech, Inc. / F. Hoffmann-La Roche Ltd.

Paul Thomas
Business Unit Head – Biosimilars,
Biocon, India

Raj Kannan
Vice President, Commercial Head, Biosimilars,
Merck, Switzerland

Huiguo (Forrest) Hu
General Manager of International Business,
Shanghai CP Guojian Pharmaceutical Co., Ltd, China

What to EXPECT in 2015:

- Current Global Biosimilars Landscape and Policy Changes
- Emerging Business and Investment Models and Opportunities
- Successful Market Access and Commercialization
- Latest Biosimilars Advances and Technology Transfer
- Clinical Developments and Approvals
- Clarifying China's Biosimilar Regulations and New Guidelines

19 May 2015 | Pre-Conference Special Focus Day

A Monoclonal Antibodies

22 May 2015 | Post-Conference Workshops

B Market Access Strategies for Biosimilars in Emerging Markets

C Gaining Approvals for Biosimilars in the US and Europe

Produced by: ibc Life Sciences, an informa business

Bronze Sponsors: BD, Finesse

Exhibitors: Agilent Technologies, fef a Novo Nordisk company, GenScript Make Research Easy

Supporting Association: SABPA

Media Partners: Asia Pacific Biotech, Asian Hospital & Healthcare Management, Bentham Science, 生物探索 biodiscover.com, Bio-Equip, BioPharma Asia, BioSpectrum, Biotech East, 世易 360GuanXi.com, GEN Genetic Engineering & Biotechnology News, ICPC.biz, Kong Posh Publications, Life Sciences Industry News, lingmed, luxresearch, Technology Networks, Pharma China

International Marketing Partner: Global Information

www.biomanufacturing-asia.com

6TH ANNUAL

BIOSIMILARS ASIA

CONFERENCE DAY ONE

20 May 2015 | Wednesday

08:00 **Registration Opens & Morning Coffee**

08:50 **Welcome Address from IBC Asia & Speed Networking**

09:00 **Chairperson's Opening Remarks**
Abdullah Baaj, *CEO*, **Boston Oncology**, USA

Biopharma Visionary Keynote Sessions

09:05 **Global Biopharma Outlook: Opportunities & Challenges 2015 & Beyond**

KEYNOTE PANEL

- Macro-analysis of the current biopharma environment and market drivers
- What are the constraints, opportunities and challenges?
- Innovation in the industry- who is taking the lead? Who are the silent players?
- How is Big Pharma and Biologics Majors reacting to the Biosimilars opportunity?
- Where are the Next Generation MaBs Biosimilars likely to come from?
- Is there money to be made from Biosimilars?
- Pros and cons of serving multiple growing markets

Moderator: **Yariv Hefez**, *Vice President Business Development, Portfolio Management, Strategy and Partnering, Biosimilars Unit*, **Merck Serono**, Switzerland

Panelists:
Abdullah Baaj, *CEO*, **Boston Oncology**, USA
Racho Jordanov, *President & CEO*, **JHL Biotech**, Taiwan
Richard O'Keeffe, *Executive Director, International Quality – Japan-Asia-Pacific (JAPAC) Regional Quality Head*, **Amgen**, Singapore

9.45 **Cutting Edge Insights into China's Growing Biotech Markets**

CEO PANEL

- Perspectives on China's biotech policies, regulation and markets
- Can Chinese Biosmilar brands compete effectively against Indian and Korean Biosimilars globally?
- Information on the local regulatory and Government policies
- Private vs publicly funded biopharma research and development
- Growth strategies and key for success in a highly competitive market

Moderator: **Shou-Bai Chao**, *Senior Vice President, Bio Ventures, Global Operations*, **AstraZeneca**, China

Panelists:
Joe Zhou, *CEO*, **Walvax Group**, China
Li Shi, *CEO*, **Shanghai Zerun Biotechnology**, China
Michelle Yu Xia, *Chairman, President & CEO*, **Akeso Biopharma**, China
Scott Liu, *CEO*, **Henlius Pharmaceuticals**, USA

10.25 **China's Evolving Biopharma Policies & Regulations**

GOVERNMENT ADDRESS

- Update on China's Biosimilars guidelines and biologic regulations
- Biomanufacturing standards
- Testing, GMP Inspections and product quality

Senior Representative, **China Food and Drug Administration (CFDA)**, China

10.50 **Morning Networking & Refreshment Break**

Biosimilars Market Landscape

11:30 **Chairperson's Opening Remarks**
Ira Jacobs, Global Oncology Lead, Biosimilars, **Pfizer**, US

11:40 **Biosimilars on the Horizon: Opportunities and Challenges**

- Myths and realities about biosimilars
- Nomenclature: biosimilars, biobetters, and intended copies
- Approaches in rapidly emerging and developing biosimilars markets
- Clinical application of biosimilars: extrapolation, interchangeability, switching, and safety

Ira Jacobs, *Global Oncology Lead, Biosimilars*, **Pfizer**, US

12.20 **Finding Symbiotic Partnerships to Accelerate Biosimilars Market Launches**

- The current situation (latest regulation guideline, clinical trial status of major players)
- How to make a suitable and feasible globalization strategy in developed regions, emerging markets and/or both?
- What are the main concerns during establishment of symbiotic partnership
  - ~ Tough and uncertain regulation
  - ~ Regional protection
  - ~ Political issues
  - ~ Money and time
  - ~ Patent risk
  - ~ Price and profit

Huiguo (Forrest) Hu, *General Manager of International Business*, **Shanghai CP Guojian Pharmaceutical Co., Ltd**, China

12:50 **Networking Lunch & VIP Tables**

VIP Table 1: Paul Thomas, *Business Unit Head – Biosimilars*, **Biocon**, India

VIP Table 2: Dr Jiang WeiDong, *Chief Science Officer and Vice President*, **Henlius Pharmaceuticals**, USA

VIP Table 3: Huiguo (Forrest) Hu, *General Manager of International Business*, **Shanghai CP Guojian Pharmaceutical Co., Ltd**, China
Exchange business cards and have an informal chat with the above guests!

2.30 **Roundtable Discussions**
Each leader will facilitate the discussion for 45 minutes. Leaders will then share key takeaways on the stage for 5 minutes each.
Choose your table now! Email **HioLeng.Lei@ibcasia.com.sg**

Roundtable 1: Emerging Investment Trends in Biosimilars and Portfolio Management
James Huang, *Managing Partner*, **KPCB**, China

Roundtable 2: Bringing Biosimilars to the Market
Dr Villoo Patell, *Founder, Chairperson and CEO*, **Avesthagen**, India

Roundtable 3: Regulatory Pathway in China
Shaoyu Chen, *Partner, Managing Director, China Food and Drug Practice*, **Covington & Burling LLP**, China

3:40 **Afternoon Networking & Refreshment Break**

Update on Biosimilars Regulations & Guidelines

4.10 **Developing Biosimilars Under CFDA Guidelines**

CASE STUDY

- How does the new guideline accelerate the development of biosimilars in China?
- Adapting and fitting your business goal and strategy into CFDA guideline
- Key success factors in implementing and developing biosimilars under new guidelines

Wen Yong, *Vice Director, Drug Research Institutes, Biopharmaceutical Institute*, **Jiangsu Aosaikang Pharmaceutical Co Ltd**, China

4.50 **Regulatory Challenges and Development in the US and Europe**

- Latest development in US and EU
- What has been changed and which market is leading the growth?
- EMA regulatory update and reworked guidelines on mABs
- Key drivers and challenges in US and Europe for Biosimilar development
- Insights on the development of the biosimilars market by 2020

Andrea Laslop, *Head of Scientific Office, Austrian Agency for Food and Health Safety, Austrian Member*, **European Medicines Agency**, Austria

5.20 **Key Criteria in Developing and Gaining Approval for Biosimilars**

CASE STUDY

- How to develop biosimilars successfully
- How to fulfill requirements and approvals in EU
- Case study on successful commercialization

Dr Shin Jae Chang, *Vice President*, **Celltrion**, Korea

5.50 **Chairperson's Summary**

6.00 **Networking Cocktail**

VIP 1: Dr Vivek Mittal, *Head – Legal*, **Lupin**, India

VIP 2: David Shen, *Vice President*, **NGM Biopharmaceuticals**, USA

VIP 3: Raj Mehta, *President – Biotech*, **Cadila Pharaceuticals Ltd**, India

Exchange business cards and visit the above guests during the networking cocktail!

7.00 **End of Conference Day One**

6TH ANNUAL

BIOSIMILARS ASIA

CONFERENCE DAY TWO

21 May 2015 | Thursday

9:00 **Chairperson's Opening Remarks**
Raj Kannan, *Vice President, Commercial Head, Biosimilars*, **Merck**, Switzerland

Latest Biosimilars Technology & Best Practice Tech Transfer

9.10 **Tips for Successful Tech Transfers**
CASE STUDY
- Complications and challenges in technology transfer
- Considerations and procedure to ensure quality and compliance
- Case study on successful technology transfer

Dr Joe Xin Hua, Zhou, *Chief Executive Officer*, **Walvax Group**, China

9.50 **SMART Technologies – More than Evolution for Biosimilars**
- The challenges of 21st Century facing the biosimilars market, from research and development to production, technology transfer, and time-to-market
- The need for biosimilars to move on to innovative and advanced smart technologies to improve productivity and achieve process excellence
- Discuss the financial benefits of SMART platform and why bioprocess control must change in order to build flexible facilities.
- Case Study: building the fast track single-use smart factory for biosimilars, with highly flexible and lower risk, scalability and universality

Dr Barbara Paldus, *CEO*, **Finesse Solutions, Inc.**, USA

10:20 **Morning Networking & Refreshment Break**

10.50 **Redefining Consistency and Reducing Risk with Cell Culture Media and Supplementation**
- Achieving significant cell culture performance and productivity improvements through cell culture process and medium optimization
- Use of hydrolysates and CD supplements on bioproduction and protein quality
- Multiple case studies

Senior Executive, **BD Advanced Bioprocessing**

Productive Development Partnerships (PDP) & Biosimilar Investments

11.20 **PDP and the Biosimilar Opportunity in LATAM**
- The biosimilar opportunity in LATAM
- The key elements of a productive development partnership (PDP)
- Decision making process regarding partner selection and tech transfer
- Business case on PDP implementation

Yariv Hefez, *Vice President Business Development, Portfolio Management, Strategy and Partnering*, **Merck Serono**, Switzerland

11.50 **Identifying the Best Investment Model and Valuating Biosimilar Opportunities**
- What attracts investors to biosimilars?
- What are common setbacks?
- Valuation of biosimilars products
- Strategic decision to maximize value (markets, partners, development costs, manufacturing)

Dr Patrik Frei, *CEO*, **Venture Valuation VV Asia**, Singapore

Market Access and Commercialization

12.20 **Developing Biosimilars/Biobetters in Emerging and Regulated Markets**
CASE STUDY
- Pricing sensitivity in biosimilars and how to achieve cost effectiveness in emerging and regulated markets?
- Ensuring speed to market and maintaining product quality while minimizing development costs
- Case study on implementation and success factors

Ko Chung Lin, *Chief Executive Officer*, **PharmaEssentia Corporation**, Taiwan

12:50 **Networking Lunch & VIP Tables**
VIP Table 1: Ko Chung Lin, *Chief Executive Officer*, **PharmaEssentia Corporation**, Taiwan

VIP Table 2: Raj Kannan, *Vice President, Commercial Head, Biosimilars*, **Merck**, Switzerland

VIP Table 3: Dr. Martina A. Sersch, *Global Clinical Lead, Oncology Global Development, APAC Biotherapeutics Lead*, **Genentech, Inc. / F. Hoffmann-La Roche Ltd.**

Exchange business cards and have an informal chat with the above guests!

2.30 **Developing Commercial Strategies to Optimize Market Uptake**
- Key considerations to optimize commercial potential:
  - ~ Size of available opportunity
  - ~ Pricing
  - ~ Reimbursement and Healthcare policies
  - ~ Competition
- Engaging the right stakeholders to drive adoption in the right patient population
- Critical success factors

Raj Kannan, *Vice President, Commercial Head, Biosimilars*, **Merck**, Switzerland

3.10 **Risks and Opportunities in Biosimilars/Biobetters and Key Enablers for Advancement**
PANEL DISCUSSION
- Considerations when expanding into Developing and Established Markets
- Addressing perception between developed and emerging markets in commercializing biosimilars
- Practical ways to understand key success factors for your products
- Adapting marketing strategies between out of pocket and reimbursed markets
- Why MNCs have not been making advancement and performing in emerging markets?
- Assessing key enablers to drive growth
- Differences and similarities between regulated and emerging markets
- Case studies and key learnings from 10 years of making and selling Biosimilars
- Success factors and new business models

Moderator: **Salman Bokhari**, *Managing Director*, **Sidrapex**, Singapore

Panelists:
Atul Deshpande, *Associate Director, Unit Strategy Office, Asia Pacific Therapeutic Strategy Unit*, **Sanofi**, China

Paul Thomas, *Business Unit Head – Biosimilars*, **Biocon**, India

Ko Chung Lin, *Chief Executive Officer*, **PharmaEssentia Corporation**, Taiwan

Tadashi Matsumoto, *President/Chief Executive Officer*, **Reqmed Co Ltd**, Japan

Dr. Kyoung E. Kim, *Vice President/ Business Development*, **Hanwha Chemical**, Korea

3:50 **Afternoon Networking & Refreshment Break**

Clinical Development

4.20 **Biosimilars Clinical Trials Development: Key Considerations in Planning and Execution**
- How to address and proactively plan a biosimilars clinical trial
- What are the complexities and bottlenecks affecting biosimilars development?
- Common issues in the clinical development of biosimilars
  - ~ Global clinical trials requirements
  - ~ Timelines/approach
  - ~ Project management
- Ways to address the challenges

Dr Arun Maseeh, *Vice President, Medical Affairs*, **Cadila Pharmaceuticals**, India

5.00 **Chairperson's Summary & End of Conference**

6TH ANNUAL

BIOSIMILARS ASIA

TAILORED WORKSHOPS

PRE-CONFERENCE SPECIAL FOCUS DAY A
19 May 2015 » Tuesday (9.00am - 4.00pm)

Monoclonal Antibodies (Mabs)

"Alvogen to market biosimilar monocolonal antibody Inflectra in Europe"

~ Pharambiz.com, Feb 2014

"Epirus Biopharmaceuticals is rolling out a knockoff of the monoclonal antibody in India with partner Ranbaxy Laboratories"

~FierceBiotech, Dec 2014

Monoclonal antibodies (MAbs) are capturing a significant share of the biosimilars market globally as a number of biologics come off patent in the next six years. Developing complex biosimilar MAbs requires a huge investment including facilities, human resources and technology as well as clear regulatory pathways.

9.00 **Chairman's Welcome and Opening Remarks**
David Shen, *Vice President*, **NGM Biopharmaceuticals**, USA

9.10 **Session 1: Trends, Challenges and Strategies for Biosimilar Therapeutic Antibody Development**
- Addressing the challenges of complex structure, tighter quality controls during production and regulatory approvals
- Learning from partnerships that led to success

Dr Sunit Maity, *AVP – Product Development*, **Theramyt Novobiologics Private Limited**, India

10:30 **Morning Networking & Refreshment Break**

11.00 **Session 2: Next Generation MAbs**
- New areas of commercial investment in next generation MAbs
- Key learnings from successful MAbs

12.15 **Networking Lunch**

13.15 **Session 3: Complexity of Monoclonal Antibodies and Clinical Challenges for Establishing Biosimilarity**
- Complexity of monoclonal Antibodies
- Challenges of establishing biosimilarity – existing regulations and guidelines
- Clinical considerations for establishing biosimilarity for mAB – sensitive populations and clinical trial design

Dr. Martina A. Sersch, *Global Clinical Lead, Oncology Global Development, APAC Biotherapeutics Lead*, **Genentech, Inc. / F. Hoffmann-La Roche Ltd.**

14:30 **Networking & Refreshment Break**

15.00 **Session 4: Proven Scalability of a Predefined Process in Bringing Biosimilar mAbs to Market**
- Using pre-defined process parameters to accelerate process development
- How to translate and commercialize mABs?
- Case studies of successful mAbs

David Shen, *Vice President*, **NGM Biopharmaceuticals**, USA

16:00 **End of Pre-conference Special Focus Day**

POST-CONFERENCE WORKSHOP B
22 MAY 2015 » FRIDAY (9.00am - 12.30pm)

Market Access Strategies for Biosimilars in Emerging Markets

Led by: **Salman Bokhari**, *Managing Director*, **Sidrapex**, Singapore

With patents set to expire on leading biologics, and payors pushing for lower prices to manage increasing healthcare costs, the demand for biosimilars is expected to grow. More biosimilars are expected to be commercialized in emerging and established markets in 3-5 years' time. What is the best commercialization strategy? What are their considerations and risks involved? What are the optimal business models for different markets?
- Commercial opportunity for biosimilars in emerging and established markets
- How will regulators assess biosimilars?
- What is the optimal go-to-market model for biosimilars?
- How will biosimilars price themselves and what are the challenges
- Launching biosimilars and successful case study

SALMAN BOKHARI has more than 35 years of successful international business and management experience with an extensive background in Asian and Middle Eastern contexts. He has an established record of delivering competitive advantage and market share gains for internationally-driven companies in startup, turnaround, and growth environments. He has a proven expertise in formulating lean operations and executing market-winning strategies. Salman is an entrepreneurial leader who drives above-average growth and profitability by repositioning businesses, establishing strategic alliances and licensing agreements, building high performance teams, and reorganizing distribution channels. From early 2001 till late 2009, Salman led the setting up of Lundbeck's country operations in Asia, and taking the lead antidepressant compound to leadership position in multiple markets. Prior to Lundbeck, Salman headed New Business Development in the Asia-Pacific Region for Schwarz Pharma, with the main focus on North Asia & China. From 1979 to early 1997, Salman was with Ciba-Geigy, later Novartis, in various headquarters and country general management roles, in Switzerland, the Middle East & Asia. Currently, Salman is based in Singapore and is a partner in a boutique life sciences consulting firm. During the last three years he has been involved in helping set up the regional and global operations of niche generic and specialty pharmaceutical companies.

POST-CONFERENCE WORKSHOP C
22 MAY 2015 » FRIDAY (1.30pm - 5.00pm)

Gaining Approvals for Biosimilars in the US & Europe

Led by: **Dr. Onesmo Mpanju**, *Principal Consultant, Independent Biopharmacuetical Product Development Consultant*, **Former Review Scientist of FDA**

With the changing regulatory environment, it is crucial for biosimilars players to understand the submission process and the regulatory guidelines for fast product approvals in the US and rest of Europe. Practical case studies and learnings will be provided along with the challenges that market players are facing.
- Update on regulatory guidelines in US and Europe
- Analytical and functional studies recommended by the US and European regulatory authorities
- What has worked in the past and what did not work
- Case study of a successful approval
- Key elements in gaining approval and expediting the process



Onesmo is an independent drug development consultant with over 23 years of experience in biopharmaceutical R&D, more than 13 years of those in regulatory affairs, including as a U.S. Food & Drug Administration (FDA) product reviewer and Regulatory Consulting Director with a global CRO. Currently based in Asia-Pacific, he has worked with biopharmaceutical companies, not-for-profit organizations, and government agencies from all corners of the globe. He has managed matrix regulatory project teams from diverse cultural and corporate or organizational backgrounds. His experience includes designing regulatory submission strategies for global development programs, CMC development planning for biologics (novel recombinant DNA products, vaccines, and complex/advanced biologics), biosimilars, and small molecules (including generic drugs), CMC due diligence auditing for asset acquisition, clinical trial compliance consulting for commercial and non-commercial sponsors, and management of clinical trial authorization (CTA/IND) or marketing (MAA/BLA) submission projects.

IBC LIFE SCIENCES

Part of BIOPHARMA DEVELOPMENT & PRODUCTION WEEK

6TH ANNUAL

BIOSIMILARS ASIA

19 - 22 May 2015

Grand Hyatt Shanghai, China

More than 80% of the forecasted spending growth is projected to be for generic drugs and biosimilars. Much of Asia's growth reflects continued growth in China — the world's second largest pharmaceutical market behind the U.S. — which is expected to reach a 2018 spending range of between $155 billion and $185 billion.

~ Genetic Engineering & Biotechnology News, Nov 2014

With continued growth and evolving market dynamics, sales of global biosimilars is forecasted to reach $25 billion in the year of 2020 and Asia is expected to ride on the uphill trend. Biosimilar regulations in key markets are expected to change and having the right commercial model plays a crucial role to accessing new markets. At IBC's Biosimilars Asia conference, top industry players will explore practical strategies for market access, new business models, investment opportunities, latest technologies and innovative case studies. Special focus will be given to the changing regulatory landscape, clinical development and approvals as well as the latest insights on Monoclonal Antibody (mAB) development.

Top Reasons to Attend:

- Gain in-depth knowledge from leading biosimilar case studies on market access and commercialization strategies
- Understand the latest development in regulations in China, US and EU
- Insights on investment opportunities and key success factors in win-win alliances and partnerships
- Learn the innovative and cost effective approaches in biosimilar development
- Gather the latest market intelligence and analysis in biosimilars R&D and Monoclonal Antibodies

Latest Case Studies:

- Celltrion's strategy in gaining approval and commercializing biosimilars in EU, US and Asia
- Merck's business model in emerging markets and technology transfer
- Shanghai CP Guojian's partnership model to accelerate biosimilar product launches
- Launch of Cadila's first cheaper copy of world's top selling drug: Adalimumab
- Learning from Biocon's key enablers for advancement
- Jiangshu Aosaikang's strategy in developing a biosimilar under new CFDA guidelines

And more...



Industries

- Generics & Biosimilar Companies **35%**
- Innovator Pharma MNCs, Biotechnology, Pharmaceuticals **20%**
- Drug Regulators, Healthcare Agencies, Government Departments **5%**
- CRAMS/CMOs **10%**
- CROs **10%**
- Patent / IP lawyers /Business Consultant **5%**
- Distribution, logistics solution **5%**
- Biopharm processing Technology provider **5%**
- Value add technology providers **5%**



Geography

- South East Asia (Singapore, Malaysia, Thailand) **5%**
- North Asia (China, Hong Kong, Korea, Japan and Taiwan) **75%**
- Europe **5%**
- USA **10%**
- Rest of the World **5%**

"Well organized, expanding the vision of Bioindustry in different countries in Asia"
TTY Biopharma

"Good opportunity to know more about Biosimilars"
Novartis

"An excellent conference with world class speakers and excellent chairperson. Well organized meeting"
IWAS

"Very nice content for strategy, regulatory, marketing & process/ manufacturing"
Genor Biopharma

"Interesting topics with convincing speakers of diversified backgrounds"
Boehringer Ingelheim

BIOPHARMA DEVELOPMENT & PRODUCTION WEEK

About the BDP Week

The Biopharma Development & Production Week is the leading industry platform for pharma, biotech, CMOs, CROs, research institutes, investors, technology and industry stakeholders to meet, network and discuss current industry trends, establish business partnerships and be updated on investment opportunities in China and surrounding Asia.

3 Conferences in 1 Location

8TH ANNUAL BIO MANUFACTURING | 6TH ANNUAL BIOSIMILARS ASIA | 4TH ANNUAL CELL LINE DEVELOPMENT & ENGINEERING ASIA

WHY YOU SHOULD SPONSOR?

Position your company as a market leader at this event and our customized Sponsorship & Exhibition package offers prime exposure to key decision-makers and exceptional branding. To explore the range of thought leadership, speaking, branding and marketing opportunities available, please contact: **Yvonne Leong** at Tel: **+65 6508 2489** OR Email: **Yvonne.Leong@ibcasia.com.sg**

REGISTER TODAY! **+65 6508 2401** **register@ibcasia.com.sg** **www.biosimilarsasia.com**

If undelivered, please return to:

IBC ASIA (S) PTE LTD
COMPANY NO: 200108203N
an informa business

111 Somerset Road,
TripleOne Somerset #10-06, Singapore 238164
Tel: +65 6508 2400 Fax: +65 6508 2408

Register 3 Delegates and the 4th Attends for Free!

6TH ANNUAL BIOSIMILARS ASIA

6 EASY WAYS TO REGISTER

MAIL the attached registration form with your cheque to
IBC Asia (S) Pte Ltd
c/o Informa Regional Business Services
111 Somerset Road,
TripleOne Somerset #10-06,
Singapore 238164

Scan the QR Code with your smartphone and register today

Customer Service Hotline
+65 6508 2401

Email
register@ibcasia.com.sg

Fax
+65 6508 2407

Web
www.biosimilarsasia.com

This label contains your priority booking code. To expedite registration, please do not remove label. If you have already received a copy of this brochure, we apologise. For reasons of confidentiality, your full particulars were not available to IBC Asia (S) Pte Ltd for deduplication prior to mail drop.

RESERVE YOUR PLACE TODAY!

☐ Yes! I/We will attend the **6th BIOSIMILARS ASIA** • 19 – 22 May 2015, Grand Hyatt Shanghai, China
☐ I would like to purchase the conference presentations at SGD1000 + GST (SGD1070) per log in.

FEE PER DELEGATE	Early Bird Rate Register & pay on or before 13 Mar 2015	Special Rate Register & pay on or before 10 Apr 2015	Normal Rate Register & pay after 10 Apr 2015	Group Rate (3 or more delegates)
International Companies (Global Headquaters Located Outside of Mainland China)				
❑ **4 Day Package:** 2 Day Conference + All Workshops	USD 2,795	USD 2,995	USD 3,195	USD 2,595
❑ **3.5 Day Package:** 2 Day Conference + Workshop A + B or C	USD 2,595	USD 2,795	USD 2,995	USD 2,395
❑ **3 Day Package:** 2 Day Conference + Workshops A or B + C	USD 2,395	USD 2,595	USD 2,795	USD 2,195
❑ **2.5 Day Package:** 2 Day Conference + Workshop B or C	USD 2,095	USD 2,295	USD 2,495	USD 1,895
❑ **2 Day Conference only**	USD 1,795	USD 1,995	USD 2,195	USD 1,595
Domestic China Companies (Global Headquaters Located within Mainland China)				
❑ **4 Day Package:** 2 Day Conference + All Workshops	CNY 7,500	CNY 8,500	CNY 9,000	CNY 7,000
❑ **3.5 Day Package:** 2 Day Conference + Workshop A + B or C	CNY 7,000	CNY 8,000	CNY 8,500	CNY 6,500
❑ **3 Day Package:** 2 Day Conference + Workshops A or B + C	CNY 6,500	CNY 7,500	CNY 8,000	CNY 6,000
❑ **2.5 Day Package:** 2 Day Conference + Workshop B or C	CNY 6,000	CNY 7,000	CNY 7,500	CNY 5,500
❑ **2 Day Conference only**	CNY 5,500	CNY 6,500	CNY 7,000	CNY 5,000

- Multiple Bookings Discount pricing is applicable to groups of 3 or more delegates from the same organisation registering for the same event, at the same time. Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR special rate OR group rate.
- All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
- Registration fees are subject to the prevailing government tax.

Delegate 1 Details

Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:

Delegate 2 Details

Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:

Please photocopy for additional delegates

Who is Head of your Department?
Who is Head of Training?

Company Information

Company Name:
Main Business/Activity:
Address:
Postal Code:

PAYMENT METHOD
(Please tick)

☐ I enclose my bankers draft / cheque payable to IBC Asia (S) Pte Ltd
☐ I am paying by bank transfer (copy attached)
☐ Payment by Credit Card. (AMEX, VISA or MasterCard accepted)

CREDIT CARD PAYMENTS
The best way to pay by credit card is through our secure on-line registration process, simply log on to the website at **www.biosimilarsasia.com** and click "Register On-line". If you would prefer to pay over the phone please complete the contact name and details and our Customer Services Team will call within 24 hours to take payment. As we treat your credit card information in the strictest confidence, please do not send payment details by email.

Credit card contact:
Department:
Direct phone number:
Email:

P46264TS

HOTEL INFORMATION

Grand Hyatt Shanghai, China
Jin Mao Tower, 88 Century Boulevard
Pudong, Shanghai 200121
Tel: +86 21 5049 1234 | Fax: +86 21 5049 8381
Contact Person: Judy Xu
Email: judy.xu@hyatt.com

PAYMENT TERMS

Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry date, registration and payment must be received by the cut-off date.

- Payment by bankers draft or cheque in S$ or US$ should be made in favour of **"IBC Asia (S) Pte Ltd"** and mailed to:
  IBC Asia (S) Pte Ltd
  c/o Informa Regional Business Services
  111 Somerset Road, TripleOne Somerset #10-06
  Singapore 238164
  Attn: The Accounts Receivable Team
- Payment by bank transfer in S$ or US$ made payable to:
  IBC Asia (S) Pte Ltd
  A/C No.:147-059513-001 (S$)
  A/C No.:260-457866-178 (US$)
  The Hongkong and Shanghai Banking Corporation Limited
  21 Collyer Quay, HSBC Building
  Singapore 049320
  Bank Swift Code: HSBCSGSG
  Bank Code: 7232
- Payment by Credit Card (AMEX, VISA or MasterCard). The best way to pay by credit card is through our secure portal built into the website. To pay by phone please indicate the contact name and details below and our Customer Services Team will call within 24 hours to take payment. Please do not send credit card information by email.

CANCELLATIONS / SUBSTITUTION

Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event.

IMPORTANT NOTE

Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407).

Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC assumes no further liability or obligation, beyond the refund of the paid registration fee, in the event of postponement or cancellation by IBC.

DATA PROTECTION

The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Occasionally, your details may be obtained from or shared with external companies who wish to communicate with you offers related to your business activities. If you do not wish your details to be used for this purpose, please contact our Database Department at Email: database@ibcasia.com.sg, Tel: +65 6508 2400 or Fax: +65 6508 2408.

REG NO. 200108203N